Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The ...

European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use ...

Presented by MedTech Europe By RORY O’NEILL PRESENTED BY View in your browser or listen to audio SNEAK PEEK — Leaders have ...

Pfizer voluntarily withdraws all lots of sickle cell disease treatment Oxbryta from worldwide markets: New York Friday, September 27, 2024, 10:00 Hrs [IST] Pfizer Inc. announced t ...

Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and ...

This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...

The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain ...

European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease ...

Pfizer has made the decision to withdraw Oxbryta (voxelotor), a treatment for sickle cell disease, from all markets where it is approved. Additionally, all clinical trials evaluating voxelotor, as ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

Sickle cell disease (SCD) is a group of painful and life-threatening genetic disorders that affect hemoglobin, the major ...

The EU's drug watchdog Thursday called for the suspension of approval for Pfizer's medicine to treat sickle cell disease, ...